These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37029815)

  • 1. Effects of immunosuppressive treatment on patient outcomes after immune checkpoint inhibitor-related gastrointestinal toxicity.
    Shatila M; Ma W; Cui Y; Naz S; S Thomas A; N De Toni E; Török HP; Khaled NB; Altan M; Schneider B; Wang Y
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7793-7803. PubMed ID: 37029815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment.
    Pizuorno Machado A; Shatila M; Glitza Oliva IC; Altan M; Siddiqui B; Zhou Y; Varatharajalu K; Zhang HC; Thomas A; Wang Y
    Am J Clin Oncol; 2023 Aug; 46(8):360-365. PubMed ID: 37219360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
    Mooradian MJ; Wang DY; Coromilas A; Lumish M; Chen T; Giobbie-Hurder A; Johnson DB; Sullivan RJ; Dougan M
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis.
    Abu-Sbeih H; Ali FS; Wang X; Mallepally N; Chen E; Altan M; Bresalier RS; Charabaty A; Dadu R; Jazaeri A; Lashner B; Wang Y
    J Immunother Cancer; 2019 Apr; 7(1):93. PubMed ID: 30940209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.
    Wang Y; Zou J; Li Y; Jiao X; Wang Y; Zhuo N; Gao M; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Shen L; Zhang H; Lu Z
    Front Immunol; 2022; 13():987568. PubMed ID: 36159840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors.
    Thomas AR; Liu C; Tong YT; Tan D; Altan M; Siddiqui BA; Shatila M; Khan A; Thomas AS; Wang Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5429-5436. PubMed ID: 36451045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.
    Verheijden RJ; Burgers FH; Janssen JC; Putker AE; Veenstra SPGR; Hospers GAP; Aarts MJB; Hehenkamp KW; Doornebosch VLE; Verhaert M; van den Berkmortel FWPJ; Chatzidionysiou K; Llobell A; Barros M; Maria ATJ; Takeji A; García Morillo JS; Lidar M; van Eijs MJM; Blank CU; Aspeslagh S; Piersma D; Kapiteijn E; Labots M; Boers-Sonderen MJ; van der Veldt AAM; Haanen JBAG; May AM; Suijkerbuijk KPM
    Eur J Cancer; 2024 Aug; 207():114172. PubMed ID: 38905818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis.
    Nara K; Taguchi S; Buti S; Kawai T; Uemura Y; Yamamoto T; Kume H; Takada T
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
    Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
    Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
    Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
    Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
    Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
    Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis.
    Hollander B; Khurana S; Jacob JS; Altan M; Wang J; Zhao D; Varatharajalu K; Alasadi M; Thomas AS; Wang Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3637-3648. PubMed ID: 35972690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events.
    Luo J; Beattie JA; Fuentes P; Rizvi H; Egger JV; Kern JA; Leung DYM; Lacouture ME; Kris MG; Gambarin M; Santomasso BD; Faleck DM; Hellmann MD
    J Thorac Oncol; 2021 Oct; 16(10):1759-1764. PubMed ID: 34265432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
    Bhatlapenumarthi V; Patwari A; Harb AJ
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint Inhibitors.
    Inomata M; Matsumoto M; Hayashi K; Seto Z; Hirai T; Tokui K; Taka C; Okazawa S; Kambara K; Imanishi S; Miwa T; Hayashi R; Matsui S; Tobe K
    Anticancer Res; 2023 Jul; 43(7):3241-3246. PubMed ID: 37351972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis.
    Moradi LA; Clark CA; Schneider CS; Deshane AS; Dobelbower MC
    Front Immunol; 2021; 12():788499. PubMed ID: 34956219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between gut microbiota and immune checkpoint inhibitor-related colitis.
    Zhou G; Zhang N; Meng K; Pan F
    Front Immunol; 2022; 13():1001623. PubMed ID: 36389768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.